Vascular  ||| S:0 E:9 ||| JJ
calcification  ||| S:9 E:23 ||| NN
and  ||| S:23 E:27 ||| CC
subendocardial  ||| S:27 E:42 ||| JJ
ischemia  ||| S:42 E:51 ||| NN
in  ||| S:51 E:54 ||| IN
hemodialysis  ||| S:54 E:67 ||| JJ
patients ||| S:67 E:75 ||| NNS
:  ||| S:75 E:77 ||| :
a  ||| S:77 E:79 ||| DT
new  ||| S:79 E:83 ||| JJ
morpho-functional  ||| S:83 E:101 ||| JJ
score  ||| S:101 E:107 ||| NN
to  ||| S:107 E:110 ||| TO
assess  ||| S:110 E:117 ||| VB
cardiovascular  ||| S:117 E:132 ||| JJ
risk ||| S:132 E:136 ||| NN
:  ||| S:136 E:138 ||| :
the  ||| S:138 E:142 ||| DT
Solofra  ||| S:142 E:150 ||| JJ
score  ||| S:150 E:156 ||| NN
ESRD  ||| S:156 E:161 ||| NNP
( ||| S:161 E:162 ||| -LRB-
end-stage  ||| S:162 E:172 ||| JJ
renal  ||| S:172 E:178 ||| JJ
disease ||| S:178 E:185 ||| NN
)  ||| S:185 E:187 ||| -RRB-
patients  ||| S:187 E:196 ||| NNS
have  ||| S:196 E:201 ||| VBP
a  ||| S:201 E:203 ||| DT
high  ||| S:203 E:208 ||| JJ
cardiovascular  ||| S:208 E:223 ||| JJ
mortality  ||| S:223 E:233 ||| NN
risk ||| S:233 E:237 ||| NN
.  ||| S:237 E:239 ||| .
A  ||| S:239 E:241 ||| DT
morphofunctional  ||| S:241 E:258 ||| JJ
approach  ||| S:258 E:267 ||| NN
of  ||| S:267 E:270 ||| IN
vascular  ||| S:270 E:279 ||| JJ
calcifications  ||| S:279 E:294 ||| NN
and  ||| S:294 E:298 ||| CC
myocardial  ||| S:298 E:309 ||| JJ
perfusion  ||| S:309 E:319 ||| NN
is  ||| S:319 E:322 ||| VBZ
needed  ||| S:322 E:329 ||| VBN
for  ||| S:329 E:333 ||| IN
the  ||| S:333 E:337 ||| DT
management  ||| S:337 E:348 ||| NN
of  ||| S:348 E:351 ||| IN
ESRD  ||| S:351 E:356 ||| NNP
patients ||| S:356 E:364 ||| NNS
.  ||| S:364 E:366 ||| .
We  ||| S:366 E:369 ||| PRP
used  ||| S:369 E:374 ||| VBD
SEVR  ||| S:374 E:379 ||| NNP
( ||| S:379 E:380 ||| -LRB-
sub-endocardial  ||| S:380 E:396 ||| JJ
viability  ||| S:396 E:406 ||| NN
ratio ||| S:406 E:411 ||| NN
)  ||| S:411 E:413 ||| -RRB-
and  ||| S:413 E:417 ||| CC
Kauppila  ||| S:417 E:426 ||| NNP
score  ||| S:426 E:432 ||| NN
from  ||| S:432 E:437 ||| IN
the  ||| S:437 E:441 ||| DT
dialysis  ||| S:441 E:450 ||| NN
population  ||| S:450 E:461 ||| NN
of  ||| S:461 E:464 ||| IN
the  ||| S:464 E:468 ||| DT
Independent  ||| S:468 E:480 ||| JJ
study  ||| S:480 E:486 ||| NN
to  ||| S:486 E:489 ||| TO
create  ||| S:489 E:496 ||| VB
a  ||| S:496 E:498 ||| DT
new  ||| S:498 E:502 ||| JJ
morpho-functional  ||| S:502 E:520 ||| JJ
score  ||| S:520 E:526 ||| NN
to  ||| S:526 E:529 ||| TO
assess  ||| S:529 E:536 ||| VB
cardiovascular  ||| S:536 E:551 ||| JJ
risk  ||| S:551 E:556 ||| NN
in  ||| S:556 E:559 ||| IN
this  ||| S:559 E:564 ||| DT
population  ||| S:564 E:575 ||| NN
( ||| S:575 E:576 ||| -LRB-
the  ||| S:576 E:580 ||| DT
Solofra  ||| S:580 E:588 ||| JJ
score ||| S:588 E:593 ||| NN
) ||| S:593 E:594 ||| -RRB-
.  ||| S:594 E:596 ||| .
184  ||| S:596 E:600 ||| CD
patients  ||| S:600 E:609 ||| NNS
were  ||| S:609 E:614 ||| VBD
followed-up  ||| S:614 E:626 ||| JJ
for  ||| S:626 E:630 ||| IN
36  ||| S:630 E:633 ||| CD
months ||| S:633 E:639 ||| NNS
.  ||| S:639 E:641 ||| .
A  ||| S:641 E:643 ||| DT
side  ||| S:643 E:648 ||| NN
lumbar  ||| S:648 E:655 ||| NN
X-ray  ||| S:655 E:661 ||| NN
was  ||| S:661 E:665 ||| VBD
performed  ||| S:665 E:675 ||| VBN
to  ||| S:675 E:678 ||| TO
assess  ||| S:678 E:685 ||| VB
vascular  ||| S:685 E:694 ||| JJ
calcifications  ||| S:694 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
lumbar  ||| S:712 E:719 ||| JJ
aorta  ||| S:719 E:725 ||| NNS
using  ||| S:725 E:731 ||| VBG
the  ||| S:731 E:735 ||| DT
Kauppila  ||| S:735 E:744 ||| JJ
score ||| S:744 E:749 ||| NN
.  ||| S:749 E:751 ||| .
Central  ||| S:751 E:759 ||| JJ
aortic  ||| S:759 E:766 ||| JJ
pressure  ||| S:766 E:775 ||| NN
and  ||| S:775 E:779 ||| CC
pulse  ||| S:779 E:785 ||| JJ
velocity  ||| S:785 E:794 ||| NN
wave  ||| S:794 E:799 ||| NN
( ||| S:799 E:800 ||| -LRB-
PWV ||| S:800 E:803 ||| NNP
)  ||| S:803 E:805 ||| -RRB-
were  ||| S:805 E:810 ||| VBD
assessed  ||| S:810 E:819 ||| VBN
at  ||| S:819 E:822 ||| IN
the  ||| S:822 E:826 ||| DT
carotid  ||| S:826 E:834 ||| JJ
artery  ||| S:834 E:841 ||| NN
site ||| S:841 E:845 ||| NN
.  ||| S:845 E:847 ||| .
Myocardial  ||| S:847 E:858 ||| JJ
perfusion  ||| S:858 E:868 ||| NN
was  ||| S:868 E:872 ||| VBD
estimated  ||| S:872 E:882 ||| VBN
with  ||| S:882 E:887 ||| IN
SEVR ||| S:887 E:891 ||| NNP
.  ||| S:891 E:893 ||| .
Independent  ||| S:893 E:905 ||| JJ
risk  ||| S:905 E:910 ||| NN
mortality  ||| S:910 E:920 ||| NN
factors  ||| S:920 E:928 ||| NNS
were  ||| S:928 E:933 ||| VBD
identified  ||| S:933 E:944 ||| VBN
with  ||| S:944 E:949 ||| IN
univariate  ||| S:949 E:960 ||| JJ
regression  ||| S:960 E:971 ||| JJ
analysis  ||| S:971 E:980 ||| NN
( ||| S:980 E:981 ||| -LRB-
p  ||| S:981 E:982 ||| CD
< ||| S:982 E:983 ||| SYM
0.01 ||| S:983 E:987 ||| CD
) ||| S:987 E:988 ||| -RRB-
;  ||| S:988 E:990 ||| :
significance  ||| S:990 E:1003 ||| NN
was  ||| S:1003 E:1007 ||| VBD
defined  ||| S:1007 E:1015 ||| VBN
as  ||| S:1015 E:1018 ||| IN
p  ||| S:1018 E:1019 ||| CD
< ||| S:1019 E:1020 ||| SYM
0.05 ||| S:1020 E:1024 ||| CD
.  ||| S:1024 E:1026 ||| .
Kauppila  ||| S:1026 E:1035 ||| JJ
score  ||| S:1035 E:1041 ||| NN
was  ||| S:1041 E:1045 ||| VBD
13±10 ||| S:1045 E:1050 ||| CD
( ||| S:1050 E:1051 ||| -LRB-
range  ||| S:1051 E:1057 ||| NN
0-24 ||| S:1057 E:1061 ||| CD
) ||| S:1061 E:1062 ||| -RRB-
;  ||| S:1062 E:1064 ||| :
PWV  ||| S:1064 E:1068 ||| NNP
was  ||| S:1068 E:1072 ||| VBD
9.5±4  ||| S:1072 E:1078 ||| CD
m ||| S:1078 E:1079 ||| CD
/ ||| S:1079 E:1080 ||| CD
sec ||| S:1080 E:1083 ||| NNS
;  ||| S:1083 E:1085 ||| :
basal  ||| S:1085 E:1091 ||| JJ
SEVR  ||| S:1091 E:1096 ||| NNP
was  ||| S:1096 E:1100 ||| VBD
1.3±0.9 ||| S:1100 E:1107 ||| CD
.  ||| S:1107 E:1109 ||| .
We  ||| S:1109 E:1112 ||| PRP
observed  ||| S:1112 E:1121 ||| VBD
an  ||| S:1121 E:1124 ||| DT
improvement  ||| S:1124 E:1136 ||| NN
of  ||| S:1136 E:1139 ||| IN
ROC  ||| S:1139 E:1143 ||| NNP
curves  ||| S:1143 E:1150 ||| NN
for  ||| S:1150 E:1154 ||| IN
SEVR  ||| S:1154 E:1159 ||| NNP
and  ||| S:1159 E:1163 ||| CC
Kauppila  ||| S:1163 E:1172 ||| NNP
score  ||| S:1172 E:1178 ||| VBP
together  ||| S:1178 E:1187 ||| RB
compared  ||| S:1187 E:1196 ||| VBN
to  ||| S:1196 E:1199 ||| TO
the  ||| S:1199 E:1203 ||| DT
ones  ||| S:1203 E:1208 ||| NNS
for  ||| S:1208 E:1212 ||| IN
SEVR  ||| S:1212 E:1217 ||| NNP
or  ||| S:1217 E:1220 ||| CC
Kauppila  ||| S:1220 E:1229 ||| NNP
score  ||| S:1229 E:1235 ||| VBP
alone ||| S:1235 E:1240 ||| RB
.  ||| S:1240 E:1242 ||| .
A  ||| S:1242 E:1244 ||| DT
quantitative  ||| S:1244 E:1257 ||| JJ
analysis  ||| S:1257 E:1266 ||| NN
of  ||| S:1266 E:1269 ||| IN
vascular  ||| S:1269 E:1278 ||| JJ
calcifications  ||| S:1278 E:1293 ||| NN
should  ||| S:1293 E:1300 ||| MD
be  ||| S:1300 E:1303 ||| VB
associated  ||| S:1303 E:1314 ||| VBN
to  ||| S:1314 E:1317 ||| TO
a  ||| S:1317 E:1319 ||| DT
qualitative  ||| S:1319 E:1331 ||| JJ
evaluation  ||| S:1331 E:1342 ||| NN
of  ||| S:1342 E:1345 ||| IN
arterial  ||| S:1345 E:1354 ||| JJ
damage  ||| S:1354 E:1361 ||| NN
to  ||| S:1361 E:1364 ||| TO
better  ||| S:1364 E:1371 ||| JJR
estimate  ||| S:1371 E:1380 ||| NN
cardiovascular  ||| S:1380 E:1395 ||| JJ
mortality  ||| S:1395 E:1405 ||| NN
risk  ||| S:1405 E:1410 ||| NN
of  ||| S:1410 E:1413 ||| IN
ESRD  ||| S:1413 E:1418 ||| NNP
patients ||| S:1418 E:1426 ||| NNS
.  ||| S:1426 E:1428 ||| .
Further  ||| S:1428 E:1436 ||| JJ
studies  ||| S:1436 E:1444 ||| NNS
are  ||| S:1444 E:1448 ||| VBP
needed  ||| S:1448 E:1455 ||| VBN
to  ||| S:1455 E:1458 ||| TO
verify  ||| S:1458 E:1465 ||| VB
our  ||| S:1465 E:1469 ||| PRP$
hypothesis ||| S:1469 E:1479 ||| NN
.  ||| S:1479 E:1481 ||| .
